Prices of Sprycel and Fuzeon to be determined shortly

Published: 2008-03-05 06:58:00

Updated: 2008-03-05 06:58:00

Pharmaceutical sources say that attention has being focused on the prices of BMS's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases and Roche's anti-AIDS agent Fuzeon (enfuvirtide) to be determined at an insurance price coordination meeting slated for the second week of this month.

The sources predict the insurance price of Sprycel will be readjusted from 69,000 won to 67,...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.